Single chain intrabodies that alter huntingtin mutant degradation
AssigneeVybion, Inc.
InventorsLee Alan Henderson, Irene Alexandra Amaro
Life of this patent
Estimating the term…
Abstract
Compositions and methods of use are provided for intrabodies that bind and alter the effects of poly-glutamate protein aggregation in poly-glutamate associated diseases, such as in Huntington's disease. Intrabodies are provided that prevent poly-glutamate aggregation, gene dysregulation, and negative effects of Huntington's disease.
Claims16
1-90. (canceled)
A method of treating or managing a subject having a disease associated with aggregation of a poly-glutamine tract protein in a cell, comprising administering to a subject in need of such treatment or management a therapeutically effective amount of an intrabody comprising an amino acid sequence comprising:
- a variable heavy sequence, a variable light chain sequence, and a linker sequence interposed between said variable heavy sequence and said variable light sequence, wherein said variable heavy sequence comprises:
- a variable heavy CDR1 sequence comprising SEQ ID NO:
- 21, a variable heavy CDR2 sequence comprising SEQ ID NO:
- 22, and a variable heavy CDR3 sequence comprising SEQ ID NO:
- 6, and wherein said variable light sequence comprising:
- a variable light CDR1 sequence comprising SEQ ID NO:
- 23, a variable light CDR2 sequence comprising SEQ ID NO:
- 24, and a variable light CDR3 sequence comprising SEQ ID NO:
- 10.
A method of treating or managing a subject having a Tau fragment pathology, comprising administering to a subject in need of such treatment or management a therapeutically effective amount of an intrabody comprising an amino acid sequence, comprising:
- a variable heavy complementarity defining region 3 (CDR3) sequence, a variable light CDR3 sequence, and a linker sequence interposed between said variable heavy CDR3 sequence and said variable light CDR3 sequence, wherein said variable heavy CDR3 sequence comprises SEQ ID NO:6, wherein said variable light CDR3 sequence comprises SEQ ID NO:10, and wherein said intrabody specifically binds to a human Tau protein.
A method for inhibiting aggregation of a poly-glutamine tract protein in a cell, comprising:
- (a) introducing into said cell a single chain intrabody comprising an amino acid sequence comprising:
- a variable heavy sequence, a variable light chain sequence, and a linker sequence interposed between said variable heavy sequence and said variable light sequence,
- said variable heavy sequence comprising:
- a variable heavy CDR1 sequence comprising SEQ ID NO:
- 21, a variable heavy CDR2 sequence comprising SEQ ID NO:
- 22, and a variable heavy CDR3 sequence comprising SEQ ID NO:
- 6, and
- said variable light sequence comprising:
- a variable light CDR1 sequence comprising SEQ ID NO:
- 23, a variable light CDR2 sequence comprising SEQ ID NO:
- 24, and a variable light CDR3 sequence comprising SEQ ID NO:
- 10;
- and
- (b) maintaining said cell produced in step (a) for a time sufficient for said intrabody to bind to said poly-glutamine tract protein, thereby preventing aggregation of poly-glutamine tract proteins in said cell.
A method for inhibiting gene dysregulation caused by aggregation of a poly-glutamine tract protein in a cell, comprising:
- (a) introducing into said cell said intrabody comprising an amino acid sequence comprising:
- a variable heavy sequence, a variable light chain sequence, and a linker sequence interposed between said variable heavy sequence and said variable light sequence,
- said variable heavy sequence comprising:
- a variable heavy CDR1 sequence comprising SEQ ID NO:
- 21, a variable heavy CDR2 sequence comprising SEQ ID NO:
- 22, and a variable heavy CDR3 sequence comprising SEQ ID NO:
- 6, and
- said variable light sequence comprising:
- a variable light CDR1 sequence comprising SEQ ID NO:
- 23, a variable light CDR2 sequence comprising SEQ ID NO:
- 24, and a variable light CDR3 sequence comprising SEQ ID NO:
- 10;
- and
- (b) maintaining said cell produced in step (a) for a time sufficient for said intrabody to bind to said poly-glutamine tract protein, thereby preventing gene dysregulation of one or more genes in said cell.
Dependencies are inferred from the claim text.